With the next clinical trial of HSC about to begin, Histogen has renewed focus on our lead product application. To this end, Histogen has ceased sales of the ReGenica products. As with all of our applications, we believe our products can best serve and be made available to customers through partnerships with industry leaders.
Thank you to our customers and those continuing to follow our story. We look forward to sharing more news with you soon. Please feel free to contact us at email@example.com with your feedback and questions.